Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
![Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira[®]](/_up/ucb_com_presscenter/images/presscenter_teaser_5.jpg?300)
Twitter Feed
-
Astonishingly, over half (54%) of vertebral fractures are missed in spine-containing CT scans. We’re working to improve this! Find out more here: https://t.co/nuB5wA7oD3 #RSNA19 https://t.co/ua73UdqW1f
— UCB News (@ucb_news) 07.12.2019 -
At this year’s #RSNA19, @jnicolaes presented a new novel screening method which aims to utilise #AI to help detect vertebral fractures, which are so often missed through current screening methods! Find out more here: https://t.co/nuB5wAp01D https://t.co/L
— UCB News (@ucb_news) 06.12.2019 -
We are proud to work alongside the global #ITP and hematology communities to develop new solutions and make a positive impact for people living with this rare but devastating condition. #ASH19 https://t.co/wgWt2HJdFk https://t.co/2fLdrDffr0
— UCB News (@ucb_news) 06.12.2019
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
